Dr. Deborah D. Proctor, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 78
Licensed in Connecticut since 1998, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: University of Cincinnati College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
CT license 037149 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Bridgeport Hospital Bridgeport, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 165
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 29 | 22 |
| Biopsy of large bowel using a flexible endoscope | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mesalamine Other prescribers in New Haven, CT | 59 |
| Stelara (ustekinumab) | 52 |
| Humira(Cf) Pen (adalimumab) Other prescribers in New Haven, CT | 35 |
| Famotidine Other prescribers in New Haven, CT | 21 |
| Pantoprazole Sodium Other prescribers in New Haven, CT | 21 |
| Omeprazole Other prescribers in New Haven, CT | 20 |
| Humira Pen (adalimumab) Other prescribers in New Haven, CT | 13 |
| Codeine Sulfate | 12 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in New Haven, CT | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $88.43 in total to this clinician.
| AbbVie Inc. | $88.43 |
|---|
| Food and Beverage | $88.43 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $11,540 in research payments for these studies, mostly to the institutions running them.
- Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Celgene Corporation · Terminated · NCT03440372 - A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Celgene Corporation · Terminated · NCT03464097 - An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Celgene Corporation · Terminated · NCT03467958 - A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. · Completed · NCT01848561 - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.